الفهرس 
صفحة العنوانOnly 14 pages are availabe for public view
 |  | from | 169 |  |  |
| | | from | 169 | | |
Abstract
Abstract
Imatinib mesylate (IM) and dipyridamole (DIM) were tested as antineoplastic targeted chemotherapeutic agents, and their anticancer potential of IM and DIM compounds against breast cancer cell line (MDA-MB231) and the related cell cycle and gene profiles. MDA-MB231 cells showed a higher sensitivity against IM than to DIM, recording an IC50values of 348 µg/mL versus 494 µg/mL for IM and DIM, respectively. The up/down regulation of Bax, Bcl2 and mitochondrial membrane potential contributing gene (MMP-1) assured the anticancer activity. Also, the apoptotic potential of DIM and IM was verified by arresting cells in the G2/M phase and increasing the percentage of the apoptotic cells in the pre-G1 phase. The antioxidant levels were drug dependent, as they were significantly higher in cells treated with IM than that treated with DIM.